Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MT-101 + fludarabine + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Myeloid Therapeutics
- Modality
- Small Molecules, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
MT-101 + fludarabine + cyclophosphamide is a combination regimen consisting of **MT-101**, an autologous mRNA-engineered chimeric antigen receptor (CAR) monocyte cell therapy targeting the CD5 surface receptor, and the lymphodepletion agents **fludarabine** (a nucleoside analog) and **cyclophosphamide** (an alkylating agent). MT-101 is designed to modify the tumor microenvironment, promote anti-tumor immunity, and specifically recognize and kill CD5+ cancer cells. The combination employs fludarabine and cyclophosphamide as lymphodepleting chemotherapy agents to reduce the patient's endogenous T cells, enhancing engraftment and function of the infused CAR monocytes[1][5][7]. MT-101 is currently developed and investigated by Myeloid Therapeutics for relapsed/refractory peripheral T-cell lymphoma (PTCL), especially CD5+ subtypes, in an ongoing phase 1/2 clinical trial.[1][5][7][9]
- Other names
- MT-101 + fludarabine + cyclophosphamide
02
Targets
DNA polymerase familyCD5 (T-cell surface glycoprotein CD5)DNA
Beyond the preview
Go deeper on MT-101 + fludarabine + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MT-101 + fludarabine + cyclophosphamide.